Donidalorsen
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Current and future therapies for bradykinin-mediated angioedema
Journal: Dermatologie (Heidelberg, Germany)
Published: May 27, 2026
Psychometric validation of the Angioedema Quality of Life Questionnaire (AE-QoL) for hereditary angioedema.
Journal: Journal of patient-reported outcomes
Published: April 02, 2026
Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1.
Journal: Journal of asthma and allergy
Published: January 21, 2026
2025 FDA TIDES (Peptides and Oligonucleotides) Harvest.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 12, 2026
Donidalorsen (Dawnzera) for prevention of hereditary angioedema attacks.
Journal: The Medical letter on drugs and therapeutics
Published: January 08, 2026
Donidalorsen for the Treatment of Hereditary Angioedema: A Review of Clinical Studies.
Journal: Drug design, development and therapy
Published: January 07, 2026
Donidalorsen for hereditary angioedema: Long-term results from a 4-year, phase 2, open-label extension study.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: December 17, 2025
Garadacimab (Andembry) for hereditary angioedema prophylaxis.
Journal: The Medical letter on drugs and therapeutics
Published: November 05, 2025
Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.
Journal: Frontiers in pharmacology
Published: October 07, 2025
Association of muscle instability and long-term prophylaxis in hereditary angioedema.
Journal: The World Allergy Organization journal
Published: September 12, 2025
Last Updated: 09/26/2026